Hitachi has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its real-time image gating system for proton beam therapy (RGPT).
The technology is used to track and irradiate tumors in motion. The system features spot scanning irradiation, which is designed to turn a narrow proton beam on and off at high speed as it changes location to irradiate entire tumor volumes.
Hitachi has been collaborating with Hokkaido University in Japan to advance particle therapy for cancer treatment. With the FDA clearance, the company plans to install RGPT at facilities in the U.S. through its Hitachi Healthcare Americas affiliate.
